H3C2 and Charlevoix-Saguenay spastic ataxia: In particular, <i>PSMC1</i>, <i>SNW1</i>, <i>H3C2</i>, <i>H1-2</i>, and <i>H2BC14</i> genes offer promising molecular targets for future therapeutic approaches in SACs.